ABBV DEF 14A DEF-14A Report May 8, 2020 | Alphaminr
AbbVie Inc.

ABBV DEF 14A Report ended May 8, 2020

ABBVIE INC.
10-Ks and 10-Qs
10-Q
Quarter ended Sept. 30, 2024
10-Q
Quarter ended June 30, 2024
10-Q
Quarter ended March 31, 2024
10-K
Fiscal year ended Dec. 31, 2023
10-Q
Quarter ended Sept. 30, 2023
10-Q
Quarter ended June 30, 2023
10-Q
Quarter ended March 31, 2023
10-K
Fiscal year ended Dec. 31, 2022
10-Q
Quarter ended Sept. 30, 2022
10-Q
Quarter ended June 30, 2022
10-Q
Quarter ended March 31, 2022
10-K
Fiscal year ended Dec. 31, 2021
10-Q
Quarter ended Sept. 30, 2021
10-Q
Quarter ended June 30, 2021
10-Q
Quarter ended March 31, 2021
10-K
Fiscal year ended Dec. 31, 2020
10-Q
Quarter ended Sept. 30, 2020
10-Q
Quarter ended June 30, 2020
10-Q
Quarter ended March 31, 2020
10-K
Fiscal year ended Dec. 31, 2019
10-Q
Quarter ended Sept. 30, 2019
10-Q
Quarter ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-K
Fiscal year ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2018
10-Q
Quarter ended June 30, 2018
10-Q
Quarter ended March 31, 2018
10-K
Fiscal year ended Dec. 31, 2017
10-Q
Quarter ended Sept. 30, 2017
10-Q
Quarter ended June 30, 2017
10-Q
Quarter ended March 31, 2017
10-K
Fiscal year ended Dec. 31, 2016
10-Q
Quarter ended Sept. 30, 2016
10-Q
Quarter ended June 30, 2016
10-Q
Quarter ended March 31, 2016
10-K
Fiscal year ended Dec. 31, 2015
10-Q
Quarter ended Sept. 30, 2015
10-Q
Quarter ended June 30, 2015
10-Q
Quarter ended March 31, 2015
10-K
Fiscal year ended Dec. 31, 2014
10-Q
Quarter ended Sept. 30, 2014
10-Q
Quarter ended June 30, 2014
10-Q
Quarter ended March 31, 2014
10-K
Fiscal year ended Dec. 31, 2013
10-Q
Quarter ended Sept. 30, 2013
10-Q
Quarter ended June 30, 2013
10-Q
Quarter ended March 31, 2013
10-K
Fiscal year ended Dec. 31, 2012
PROXIES
DEF 14A
Filed on March 18, 2024
DEF 14A
Filed on March 20, 2023
DEF 14A
Filed on March 21, 2022
DEF 14A
Filed on March 22, 2021
DEF 14A
Filed on March 23, 2020
DEF 14A
Filed on March 22, 2019
DEF 14A
Filed on March 19, 2018
DEF 14A
Filed on March 20, 2017
DEF 14A
Filed on March 21, 2016
DEF 14A
Filed on March 20, 2015
DEF 14A
Filed on March 24, 2014
DEF 14A
Filed on March 15, 2013
TABLE OF CONTENTS
Proxy Statement SummaryInformation about the Annual MeetingWho Can VoteNotice and AccessVoting by ProxyRevoking a ProxyDiscretionary Voting AuthorityQuorum and Vote Required to Approve Each Item on the ProxyEffect of Broker Non-Votes and AbstentionsInspectors of ElectionCost of Soliciting ProxiesAbbVie Savings PlanInformation Concerning Director Nominees (Item 1)The Board of Directors and its CommitteesCommunicating with the Board of DirectorsDirector CompensationSecurities OwnershipExecutive CompensationCompensation Discussion and AnalysisCompensation Committee ReportCompensation Risk AssessmentSummary Compensation Table2019 Grants of Plan-Based Awards2019 Outstanding Equity Awards at Fiscal Year End2019 Option Exercises and Stock VestedPension BenefitsNon-Qualified Deferred CompensationPotential Payments upon Termination or Change in ControlRatification of Ernst & Young LLP as AbbVie's Independent Registered Public Accounting Firm (Item 2)Audit InformationAudit Fees and Non-Audit FeesPolicy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of the Independent Registered Public Accounting FirmAudit Committee ReportSay on PayAdvisory Vote on the Approval of Executive Compensation (Item 3)Management Proposal to Eliminate Supermajority Voting (Item 4)Stockholder ProposalsStockholder Proposal on Lobbying Report (Item 5)Stockholder Proposal on Independent Chair (Item 6)Stockholder Proposal on Compensation Committee Drug Pricing Report (Item 7)Additional Information